• Steris recently entered the spotlight as investors reacted to expectations around its now-past fiscal first-quarter 2027 earnings release, with analysts having projected a 7.7% increase in profit per share versus the prior year and pointing to a solid record of meeting or beating estimates.
• What stands out is how this anticipated profit improvement, combined with Steris’s track record in recent quarters, appears to be shaping confidence in the company’s ability to sustain its earnings profile.
• We’ll now examine how expectations for stronger earnings per share and recent estimate-beating history influence Steris’s broader investment narrative and risks.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

STERIS Investment Narrative Recap

To own STERIS, you need to believe in steady demand for infection prevention products and services, supported by recurring consumables and service revenue. The anticipated 7.7% profit per share increase reinforces the near term earnings catalyst, but does not materially change the key risks around healthcare reimbursement pressure and tariff driven cost inflation.

The recent FY2027 guidance for 7% to 8% reported revenue growth is the most relevant backdrop to these earnings expectations, as it frames how sustained order intake and capital investment could support STERIS’s earnings profile. Together with ongoing share repurchases and a stable dividend, this guidance shapes how investors weigh tariff exposure, reimbursement risks, and M&A execution against the earnings outlook.

Yet while earnings expectations look constructive, investors should be aware of how rising metal tariffs and reimbursement pressures could...

STERIS' narrative projects $7.2 billion revenue and $1.1 billion earnings by 2029. This requires 6.6% yearly revenue growth and about a $300 million earnings increase from $782.3 million today.

Uncover how STERIS' forecasts yield a $256.86 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Three STERIS fair value estimates from the Simply Wall St Community cluster between US$230 and about US$256.86, showing how differently individual investors view upside. You can weigh these against the current earnings focused catalyst and consider how reimbursement and tariff risks might influence your own assessment of STERIS’s future performance.

Explore 3 other fair value estimates on STERIS - why the stock might be worth just $230.00!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your STERIS research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free STERIS research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate STERIS' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.